SavedAdd your journal

Journals / Balkan Medical Journal / 2019 / Cilt: 36 - Sayı: 6

Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome

Yuan-Chuang ZHAO
Ting HU
Ke-Tao Du
Yan CHEN
Pages
331–336
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A visual analog scale and the Revised Fibromyalgia Impact Questionnaire were utilized to assess the degree of pain and functional abilities.Results: Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were significantly greater in patients with fibromyalgia compared with healthy controls (151.6±31.9 pg/mL vs 103.3±25.2 pg/mL, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Elevated levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 have been identified in fibromyalgia patients.Aims: To examine the potential association among serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 with disease severity of fibromyalgia.Study Design: Cross-sectional study.Methods: Seventy-nine female patients with fibromyalgia and 75 healthy normal controls were included in our study.
📊
Key Findings & Data:Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were detected by enzyme-linked immune sorbent assays.
💡
Conclusion & Impact:A visual analog scale and the Revised Fibromyalgia Impact Questionnaire were utilized to assess the degree of pain and functional abilities.Results: Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were significantly greater in patients with fibromyalgia compared with healthy controls (151.6±31.9 pg/mL vs 103.3±25.2 pg/mL, p
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Elevated levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 have been identified in fibromyalgia patients.Aims: To examine the potential association among serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 with disease severity of fibromyalgia.Study Design: Cross-sectional study.Methods: Seventy-nine female patients with fibromyalgia and 75 healthy normal controls were included in our study. Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were detected by enzyme-linked immune sorbent assays. The existence of tender points was evaluated based on the standardized manual tender point examination. Pressure pain thresholds at the knees, and bilateral trapezius muscles were measured with an algometer. A visual analog scale and the Revised Fibromyalgia Impact Questionnaire were utilized to assess the degree of pain and functional abilities.Results: Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were significantly greater in patients with fibromyalgia compared with healthy controls (151.6±31.9 pg/mL vs 103.3±25.2 pg/mL, p

🔖

Cite This Article

ZHAO, Y., HU, T., Du, K., CHEN, Y. (2022). Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome. Balkan Medical Journal, Cilt: 36 - Sayı: 6, 331–336. https://ajindex.com/articles/461226

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Liedberg GM, Henriksson CM. Factors of importance for work disability in women with fibromyalgia: an interview study. Arthritis Rheum 2002;47:266-74.
  2. Talotta R, Bazzichi L, Di Franco M, Casale R, Batticciotto A, Gerardi MC, et al. One year in review 2017: fibromyalgia. Clin Exp Rheumatol 2017;35:6-12.
  3. Sumpton JE, Moulin DE. Fibromyalgia. Handb Clin Neurol 2014;119:513-27.
  4. Wolfe F, Walitt BT, Katz RS, Häuser W. Social security work disability and its predictors in patients with fibromyalgia. Arthritis Care Res (Hoboken) 2014;66:1354-63.
  5. Clauw DJ, D'Arcy Y, Gebke K, Semel D, Pauer L, Jones KD. Normalizing fibromyalgia as a chronic illness. Postgrad Med 2018;130:9-18. Coskun Benlidayi I. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int 2019;39:781-91.
  6. Wang J, Knaut H. Chemokine signaling in development and disease. Development 2014;141:4199-205.
  7. Stone MJ, Hayward JA, Huang C, Huma ZE, Sanchez J. Mechanisms of Regulation of the Chemokine-Receptor Network. Int J Mol Sci 2017:8. Buck AK, Stolzenburg A, Hänscheid H, Schirbel A, Lückerath K, Schottelius M, et al. Chemokine receptor - Directed imaging and therapy. Methods 2017;130:63-71.
  8. Cecchinato V, Uguccioni M. Insight on the regulation of chemokine activities. J Leukoc Biol 2018;104:295-300.
  9. Proost P, Struyf S, Van Damme J, Fiten P, Ugarte-Berzal E, Opdenakker G. Chemokine isoforms and processing in inflammation and immunity. J Autoimmun 2017;85:45-57.
  10. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313-26.
  11. O'Connor T, Borsig L, Heikenwalder M. CCL2-CCR2 Signaling in Disease Pathogenesis. Endocr Metab Immune Disord Drug Targets 2015;15:105-18.
  12. Raghu H, Lepus CM, Wang Q, Wong HH, Lingampalli N, Oliviero F, et al. CCL2/ CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Ann Rheum Dis 2017;76:914-22.
  13. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011;10:276-81.
  14. Lin J, Kakkar V, Lu X. Impact of MCP-1 in atherosclerosis. Curr Pharm Des 2014;20:4580-8.
  15. Zhang Z, Cherryholmes G, Mao A, Marek C, Longmate J, Kalos M, et al. High Plasma Levels of MCP-1 and Eotaxin Provide Evidence for an Immunological Basis of Fibromyalgia. Exp Biol Med (Maywood) 2008;233:1171-80.
  16. Alvarez P, Green PG, Levine JD. Role for monocyte chemoattractant protein-1 in the induction of c